Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leif Smith

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Discovery|December 3, 2017
Improving the attrition rate of Lanthipeptide discovery for commercial applicationsMengxin Geng, Leif Smith
Expert Opinion on Drug Discovery|May 26, 2015
Multipronged approach for engineering novel peptide analogues of existing lantibioticsJerome Escano, Leif Smith
Antibiotics (Basel, Switzerland)|September 23, 2022
Occidiofungin: Actin Binding as a Novel Mechanism of Action in an Antifungal AgentNopakorn Hansanant, Leif Smith
Expert Opinion on Drug Discovery|December 12, 2024
Approach advancements for engineering novel peptide analogs of existing lantibiotics: where are we today?Thushinari Joseph, Leif Smith
Applied and Environmental Microbiology|May 20, 2018
Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and StabilityMengxin Geng, Leif Smith
Current Opinion in Microbiology|October 14, 2008
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibioticsLeif Smith, Jd Hillman
Recent Patents on Anti-Infective Drug Discovery|November 26, 2009
Medical claims and current applications of the potent echinocandin antifungalsLeif Smith, Shi-En Lu
Recent Patents on Anti-Infective Drug Discovery|April 27, 2011
Commercial development and application of type A lantibioticsShawanda Wilson-Stanford, Leif Smith
Microorganisms|March 27, 2025
<i>Streptococcus salivarius</i> and <i>Ligilactobacillus salivarius</i>: Paragons of Probiotic Potential and Reservoirs of Novel AntimicrobialsMcKinley D Williams, Leif Smith
Trends in Microbiology|June 17, 2020
Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious DiseasesAbdelahhad Barbour, Philip Wescombe, Leif Smith
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Discovery|December 3, 2017
Improving the attrition rate of Lanthipeptide discovery for commercial applicationsMengxin Geng, Leif Smith
Expert Opinion on Drug Discovery|May 26, 2015
Multipronged approach for engineering novel peptide analogues of existing lantibioticsJerome Escano, Leif Smith
Antibiotics (Basel, Switzerland)|September 23, 2022
Occidiofungin: Actin Binding as a Novel Mechanism of Action in an Antifungal AgentNopakorn Hansanant, Leif Smith
Expert Opinion on Drug Discovery|December 12, 2024
Approach advancements for engineering novel peptide analogs of existing lantibiotics: where are we today?Thushinari Joseph, Leif Smith
Applied and Environmental Microbiology|May 20, 2018
Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and StabilityMengxin Geng, Leif Smith
Current Opinion in Microbiology|October 14, 2008
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibioticsLeif Smith, Jd Hillman
Recent Patents on Anti-Infective Drug Discovery|November 26, 2009
Medical claims and current applications of the potent echinocandin antifungalsLeif Smith, Shi-En Lu
Recent Patents on Anti-Infective Drug Discovery|April 27, 2011
Commercial development and application of type A lantibioticsShawanda Wilson-Stanford, Leif Smith
Microorganisms|March 27, 2025
<i>Streptococcus salivarius</i> and <i>Ligilactobacillus salivarius</i>: Paragons of Probiotic Potential and Reservoirs of Novel AntimicrobialsMcKinley D Williams, Leif Smith
Trends in Microbiology|June 17, 2020
Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious DiseasesAbdelahhad Barbour, Philip Wescombe, Leif Smith
Pageof 5